DiaMedica Therapeutics Inc.(DMAC)Earnings, Financials & Key RatiosDiaMedica Therapeutics Inc. (DMAC) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's current cash position of $4.9 million against a quarterly operating loss of $10.5 million suggests a precarious financial runway that may necessitate dilutive financing.
DiaMedica Therapeutics Inc. (DMAC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
DiaMedica Therapeutics Inc. (DMAC) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.19vs $0.17-11.8% | —vs $14M |
| Q2 2026 | Mar 30, 2026 | $0.17vs $0.17+0.0% | — |
| Q4 2025 | Nov 12, 2025 | $0.17vs $0.15-13.3% | — |
| Q3 2025 | Aug 12, 2025 | $0.18vs $0.18+0.0% | — |
Recent stock market news and headlines for DiaMedica Therapeutics Inc. (DMAC)
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction a
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alfa) for the treatment of fetal growth restriction (FGR). This is the first clinical evaluation of DM199 in FGR. The open-label, single-arm study is design.
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development of DM199 (rinvecalinase alfa) for the treatment of preeclampsia (PE). DiaMedica believes, based on the FDA's feedback, that the previously completed rat reproductive toxi.
Key metrics vs top competitors for DiaMedica Therapeutics Inc. (DMAC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $8.01 | $431.61M | -11.44 | — | — | -67.68% | — | |
| $4.34 | $17.12M | -0.17 | — | — | -381.01% | — | |
| $98.52 | $6.52B | 71.91 | 15.24% | 9.48% | 5.13% | — | |
| $4.92 | $34.41M | -0.14 | — | — | — | — | |
| $16.03 | $214.81M | -21.09 | -5.91% | -9.52% | -7.74% | — | |
| $313.50 | $9.06B | -23.26 | -100% | — | -43.02% | — |
DiaMedica Therapeutics Inc. (DMAC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DiaMedica Therapeutics Inc. (DMAC) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 21, 2026·SEC
May 6, 2026·SEC
Mar 31, 2026·SEC
Get notified when DMAC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DiaMedica Therapeutics Inc. (DMAC) stock FAQ — growth, dividends, profitability & financials explained
DiaMedica Therapeutics Inc. (DMAC) reported a net loss of $35.1M for fiscal year 2025.
DiaMedica Therapeutics Inc. (DMAC) has a return on equity (ROE) of -67.7%. Negative ROE indicates the company is unprofitable.
DiaMedica Therapeutics Inc. (DMAC) had negative free cash flow of $31.1M in fiscal year 2025, likely due to heavy capital investments.
